Patent ID: 8685955

Claim:
A method for treatment of a neurodegenerative or cerebrovascular disease, condition or disorder, which comprises administering to an individual in need thereof an effective amount of a compound of formula I to IV or a pharmaceutically acceptable salt thereof: wherein R 1 is a residue of an analog of a neuroprotective peptide, or of a fragment thereof, containing a cysteine residue that is linked to the C atom via the â€”Sâ€” atom of the L- or D-Cys residue, and wherein the amino terminal of the peptide is unsubstituted or substituted by a hydrophobic group; R 2 is, NHâ€”X; R 3 is a group selected from the group consisting of â€”NHâ€”CH 2 â€”CH 2 â€”NHâ€”R 4 , â€”CR 5 R 6 R 7 , â€”N(CH 3 )â€”X, â€”N(R 8 )â€”CH(CH 2 SH)COOC 2 H 5 , â€”N(R 8 )â€”CH 2 â€”COOCH 2 C 6 H 5 , and â€”Sâ€”CH 2 â€”CH(COOH)â€”NHR 8 â€²; R 4 is a group selected from the group consisting of X, COOC 2 H 5 , (CH 2 ) 2 â€”Oâ€”R 8 , and â€”COOâ€”(CH 2 ) 2 â€”NHâ€”R 8 ; R 5 is H, C 1 -C 4 lower alkyl or COOC 2 H 5 ; R 6 is H, COOH, COOâ€” or COOC 2 H 5 ; R 7 is selected from the group consisting of â€”NHâ€”R 8 , NHâ€”COCHâ€”NHâ€”NHâ€”R 8 , and â€”NHâ€”NHâ€”COâ€”CH(CH 2 OH)â€”NHâ€”R 8 ; R 8 is X; Râ€² 8 is X; â€”COâ€”CH 2 R 12 â€”â€”COâ€”CH 2 â€”COâ€”CH 2 R 11 is a group selected from the group consisting of (i) â€”Sâ€”CH 2 â€”CH(COOH)â€”NHâ€”X; (ii) â€”N(X)â€”CH 2 COOâ€”CH 2 â€”C 6 H 5 ; (iii) â€”N(CH 3 )â€”X; (iv) â€”N(X)â€”CH(CH 2 SH)COOC 2 H 5 ; (v) â€”CH 2 â€”NHâ€”NHâ€”COâ€”CH(CH 2 OH)â€”NHâ€”X; (vi) â€”C(CH 3 )(COOH)â€”NHâ€”NHâ€”X; (vii) â€”CH(COOH)â€”NHâ€”X; (viii) â€”CH(COOC 2 H 5 H)â€”NHâ€”X; and R 12 is X, C 1 -C 4 lower alkyl, COOC 2 H 5 or â€”(CH 2 ) 2 â€”OHâ€”; R 13 is X, â€”CH 2 ) 2 â€”OXâ€”, or â€”COOâ€”(CH 2 ) 2 â€”NHâ€”X; and X is a propargyl group.